European Society of Cardiology: Aficamten is Superior to Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy
August 30, 2025
August 30, 2025
SOPHIA ANTIPOLIS, France, Aug. 30 -- The European Society of Cardiology issued the following news release:
* * *
Aficamten is superior to metoprolol for symptomatic obstructive hypertrophic cardiomyopathy
* Beta-blockers are commonly used in the initial treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM), despite limited evidence of their efficacy.
* The MAPLE-HCM trial compared the cardiac myosin inhibitor, aficamten, with . . .
* * *
Aficamten is superior to metoprolol for symptomatic obstructive hypertrophic cardiomyopathy
* Beta-blockers are commonly used in the initial treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM), despite limited evidence of their efficacy.
* The MAPLE-HCM trial compared the cardiac myosin inhibitor, aficamten, with . . .